Filing Flows › 20/20 Biolabs (AIDX) › How it makes money
How 20/20 Biolabs (AIDX) makes money
20/20 Biolabs (AIDX) made $731K of revenue in the second quarter 2026 (Q2 2026), +42% from a year earlier. OneTest brought in $696K (95%); BioCheck brought in $35K (5%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| OneTest | $696K | 95.3% | +124% | +47% |
| BioCheck | $35K | 4.7% | +61% | -15% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $731K | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $731K | +36% |
| Q1 2026 | $353K | -36% |
From 20/20 Biolabs' 10-Q filed Aug 14, 2026 (on EDGAR).
Questions
How does 20/20 Biolabs make money?
20/20 Biolabs (AIDX) made $731K of revenue in the second quarter 2026 (Q2 2026), +42% from a year earlier. OneTest brought in $696K (95%); BioCheck brought in $35K (5%).
What is 20/20 Biolabs' biggest business?
OneTest: $696K in the second quarter 2026, 95% of revenue, +47% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.